This observational study with circulating tumor cells (CTC) count, isolation and analysis at several time points during disease progression is to investigate the role and biology of CTCs and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as biomarkers, and aims at the identification of key signaling networks that are active in CTCs.
Study Type
OBSERVATIONAL
Enrollment
3,000
Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
University Hospital Basel
Basel, Switzerland
RECRUITINGDepartment Oncology, Haematology & Immuntherapy, Kantonsspital Baselland
Liestal, Switzerland
RECRUITINGOverall survival (OS) in heterogeneous cancer population
overall survival (OS) in heterogeneous cancer population
Time frame: Screening (Visit 1) until the date of death (assessed up to 240 months)
Change in total number of isolated CTCs
Change in total number of isolated CTCs
Time frame: Through study completion, an average of 20 years
Progression free survival (PFS)
progression free survival (PFS) in the different cancer cohorts with different treatment regimes
Time frame: Through study completion, an average of 20 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.